|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Acceleron Pharma Announces the Initiation of Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients With Ovarian Cancer
2/5/2013 10:48:38 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer. Dalantercept is a novel protein therapeutic that targets the activin receptor-like kinase 1 (ALK1) pathway and inhibits angiogenesis through a mechanism distinct from that of anti-angiogenic therapies currently used to treat various cancers. The phase 2, open-label study is chaired by Robert Burger, M.D., Director of the Women’s Cancer Center and Professor at the Department of Surgical Oncology at the Fox Chase Cancer Center in Philadelphia, Pa. Acceleron, its partners, and collaborators have now initiated seven phase 2 studies across three of Acceleron’s programs – dalantercept (ACE-041), sotatercept (ACE-011), and ACE-536 – since November of 2012.
|
|
|
|
|
|
|
|
|
|
|